

**Isolation and identification of a novel anti-diabetic compound
from *Euclea undulata* Thunb.**

by

Miranda Susan Deutschländer

Submitted in partial fulfillment of the requirements for the degree

**Philosophy Scientiae
In Plant Sciences**

**In the Faculty of Nature and
Agricultural Sciences
(Department of Plant Science)
University of Pretoria
Pretoria**

**Supervisor: Prof. Namrita Lall
Co-supervisor: Dr. Maryna van de Venter**

2010



Declaration

I declare that this thesis, which I hereby submit for the degree PhD Plant Science at the University of Pretoria is my own work and has not previously been submitted by me for a degree at this or any other tertiary institution.

Signature:

Date:

Isolation and identification of a novel anti-diabetic compound from *Euclea undulata* Thunb.

By

Miranda Susan Deutschländer

Supervisor: Prof. Namrita Lall
Co-supervisor: Dr. Maryna van de Venter
Department: Plant Science
Degree: Philosophiae Doctor

Abstract

Four plant species traditionally used for the treatment of diabetes by South African traditional healers and herbalists were investigated for hypoglycaemic activity. Species included *Schkuhria pinnata* (Lam.) Cabrera, *Pteronia divaricata* (P.J. Bergius) Less *Elaeodendron transvaalense* (Burt Davy) R.H. Archer and *Euclea undulata* Thunb var. *myrtina* (Burch.) Hiern.

Acetone and ethanol plant extracts were prepared and tested *in vitro*, for glucose utilization, at concentrations of 12.5 µg/ml on three cell lines namely; Murine C2C12 myocytes, Chang liver cells and 3T3-L1 preadipocytes. Metformin, at a concentration of 1 µM (0.166 µg/ml) was used as positive control for hepatic cells and insulin at a concentration 1 µM (5.7 µg/ml) for myocytes and preadipocytes. Toxicity tests were done for all extracts on preadipocytes and hepatic cells, but not on myocytes as these cells were exposed to the extract for only a short period (1 hour) during the hypoglycaemic bioassay. Preadipocytes and hepatic cells were exposed to the plant extracts for 48 hours. The four plant extracts were further investigated for hypoglycaemic activity by evaluating inhibiting effects on carbohydrate-hydrolysing enzymes alpha-glycosidase and alpha-amylase.

In vitro hypoglycaemic analysis revealed that acetone and ethanol plant extracts of *S. pinnata*, *E. undulata* and *E. transvaalense*, displayed hypoglycaemic activity in one or more of the various cell lines, whereas, *P. divaricata* showed no hypoglycaemic activity. The best results were obtained with the ethanol and acetone extracts of *S. pinnata* in

preadipocytes with a glucose uptake of 148.2% and 79.6% respectively, above control (100%). However, about 50% preadipocytes survived on exposure to the extracts of *S. pinnata* at 12.5 µg/ml indicating significant cytotoxicity. Glucose uptake of 63.3% was observed by the ethanol extract of *S. pinnata* on hepatic cells. *E. transvaalense* showed hypoglycaemic activity on preadipocytes exhibiting glucose uptake of 38.6% above control 100%. Glucose uptake of 62.2 % were obtained by the *E. undulata* extract in C2C12 myocytes, with 100% cell viability. *E. undulata* scored a +3 and was chosen for further analysis. Antidiabetic activity and toxicity of the plant extracts were taken into consideration when scoring was applied.

Alpha-glucosidase and alpha-amylase results indicated that *P. divaricata* extract inhibited alpha-glucosidase (IC₅₀ 31.22 µg/ml) whereas *E. undulata* (IC₅₀ 2.80 µg/ml) and *E. transvaalense* (IC₅₀ 1.12 µg/ml) extracts inhibited alpha-amylase. Results obtained indicated that all four plant extracts tested have the ability to lower blood glucose levels to some extent and in different manners and therefore corroborate the ethnomedicinal use of these four species in the treatment of diabetes.

Phytochemical studies of a crude acetone extract of the root bark of *E. undulata* var. *myrtina* produced a new α-amyrin-3O-β-(5-hydroxy) ferulic acid compound (**1**), and three known compounds; betulin (**2**), lupeol (**3**) and epicatechin (**4**). The chemical structures were determined by spectroscopic means. *In vitro* assays on C2C12 myocytes revealed that (**2**) (21.4%) and (**4**) (166.3%) were active in lowering blood glucose levels whereas (**1**) (IC₅₀ 4.79 µg/ml) and to a lesser extent (**4**) (IC₅₀ 5.86 µg/ml) and (**3**) (IC₅₀ 6.27 µg/ml) inhibited alpha-glucosidase. These results indicated that the crude, *E. undulata* acetone extract does contain compounds that display hypoglycaemic activity.

The hypoglycaemic activity of four plant species including *E. undulata*, and the four isolated purified compounds, are reported for the first time.

Table of Contents

DECLARATION	2
SUMMARY	3
CHAPTER 1.	
DIABETES:LITERATURE REVIEW	14
1.1. INTRODUCTION	14
1.2. CLASSIFICATION OF DIABETES MELLITUS	15
1.2.1 Insulin dependant diabetes mellitus (IDDM)	16
1.2.2 Non-insulin dependant diabetes mellitus (NIDDM)	17
1.3. DIABETES MELLITUS IN AFRICA	18
1.4. RATIONALE	19
1.5. PATHOPHYSIOLOGY OF DIABETES MELLITUS	19
1.5.1 Physiological mechanisms and management	19
1.5.1.1 The endocrine pancreas.....	19
1.5.1.2 Diabetes-related islet changes.....	20
1.5.2 Insulin	20
1.5.2.1 Insulin secretion	21
1.5.2.2 Insulin degradation	22
1.5.2.3 The insulin receptor.....	23
1.5.2.4 Effects of insulin on its targets.....	23
1.5.2.5 Action of insulin on glucose transporters (GLUT).....	23
1.5.2.6 Action of insulin on liver	24
1.5.2.7 Effect of insulin on muscle.....	25
1.5.2.8 Effect of insulin on adipose tissue.....	25
1.6 Complications of insulin therapy	26
1.7 Oral antidiabetic agents	26
1.7.1 Insulin secretagogues: sulfonylureas.....	26
1.7.2 Insulin secretagogues: meglitinides.....	26
1.7.3 Biguanides	28
1.7.4 Thiazolidinediones	28
1.7.5 Alpha-glucosidase inhibitors.....	30
1.8 Herbal products currently available in South Africa for the treatment of diabetes	30
1.9 Hypothesis and objectives of this study	31
1.10 Scope of this thesis	32
1.11 Conclusions	32
1.12 References	33

CHAPTER 2.

PLANT SPECIES USED IN THE TREATMENT OF DIABETES BY SOUTH AFRICAN TRADITIONAL HEALERS: AN INVENTORY38

2.1 Abstract	39
2.2 Introduction	39
2.3 Ethnobotany in South Africa	41
2.4 Plant Material	42
2.4.1. <i>Elaeodendron transvaalense</i>	42
2.4.1.1 Description.....	42
2.4.1.2 Medicinal uses.....	42
2.4.1.3 Phytochemistry / Bioactivity	43
2.4.2 <i>Euclea undulata</i>	43
2.4.2.1 Description.....	43
2.4.2.2 Medicinal uses.....	44
2.4.2.3 Phytochemistry / Bioactivity	44
2.4.3 <i>Euclea natalensis</i>	45
2.4.3.1 Description.....	45
2.4.3.2 Medicinal uses.....	45
2.4.3.3 Phytochemistry/ Bioactivity.....	46
2.4.4 <i>Lannea edulis</i>	46
2.4.4.1 Description.....	46
2.4.4.2 Medicinal uses.....	46
2.4.4.3 Phytochemistry / Bioactivity	47
2.4.5 <i>Spirostachys africanus</i>	47
2.4.5.1 Description.....	47
2.4.5.2 Medicinal uses.....	47
2.4.5.3 Phytochemistry / Bioactivity	47
2.4.6 <i>Schkuhria pinnata</i>	48
2.4.6.1 Description.....	48
2.4.6.2 Medicinal uses.....	48
2.4.7 <i>Pteronia divaricata</i>	49
2.4.7.1 Description.....	49
2.4.7.2 Medicinal uses	50
2.4.8 <i>Ziziphus mucronata</i>	50
2.4.8.1 Description.....	50
2.4.8.2 Medicinal uses.....	50
2.4.8.3 Phytochemistry / Bioactivity	51
2.4.9 <i>Aloe ferox</i>	51
2.4.9.1 Description.....	51

2.4.9.2 Medicinal uses.....	52
2.4.9.3 Phytochemistry / Bioactivity.....	52
2.4.10 <i>Warburgia salutaris</i>	52
2.4.10.1 Description	52
2.4.10.2 Medicinal uses	53
2.4.10.3 Phytochemistry / Bioactivity	53
2.4.11 <i>Momordica balsamina</i>	53
2.4.11.1 Description.....	54
2.4.11.2 Medicinal uses.....	54
2.4.11.3 Phytochemistry / Bioactivity	54
2.4.12 <i>Kederostis nana</i>	55
2.4.12.1 Description.....	55
2.4.12.2 Medicinal uses.....	55
2.4.13 <i>Artemisia afra</i>	56
2.4.13.1 Description.....	56
2.4.13.2 Medicinal uses.....	56
2.4.13.3 Phytochemistry / Bioactivity	57
2.4.14 <i>Catharanthus roseus</i>	57
2.4.14.1 Description	58
2.4.14.2 Medicinal uses	58
2.4.14.3 Phytochemistry / Bioactivity	58
2.4.15 <i>Cnicus benedictus</i>	58
2.4.15.1 Description	59
2.4.15.2 Medicinal uses	59
2.4.15.3 Phytochemistry / Bioactivity	59
2.4.16 <i>Psidium guajava</i>	60
2.4.16.1 Description.....	60
2.4.16.2. Medicinal uses	60
2.4.16.3 Phytochemistry / Bioactivity	60
2.4.17 <i>Terminalia sericea</i>	61
2.4.17.1 Description.....	61
2.4.17.2 Medicinal uses.....	61
2.4.17.3 Phytochemistry / Bioactivity	62
2.4.18 <i>Sutherlandia frutescens</i>	62
2.4.18.1 Description	62
2.4.18.2 Medicinal uses	62
2.4.18.3 Phytochemistry / Bioactivity	63
2.4.19 <i>Bridelia micrantha</i>	63
2.4.19.1 Description	63

2.4.19.2 Medicinal uses	64
2.4.19.3 Phytochemistry / Bioactivity	64
2.4.20 <i>Sclerocarya birrea</i>	64
2.4.20.1 Description	64
2.4.20.2 Medicinal uses.....	65
2.4.20.3 Phytochemistry / Bioactivity.....	65
2.4.21 <i>Brachylaena discolor</i>	65
2.4.21.1 Description	65
2.4.21.2 Medicinal uses	66
2.4.21.3 Phytochemistry / Bioactivity	66
2.4.22 <i>Brachylaena elliptica</i>	66
2.4.22.1 Description	66
2.4.22.2 Medicinal uses	67
2.4.22.3 Phytochemistry / Bioactivity	67
2.4.23 <i>Brachylaena ilicifolia</i>	67
2.4.23.1 Description	67
2.4.23.2 Medicinal uses	68
2.4.23.3 Phytochemistry / Bioactivity	68
2.4.24 <i>Bulbine latifolia</i>	68
2.4.24.1 Description.....	68
2.4.24.2 Medicinal uses.....	68
2.4.24.3 Phytochemistry / Bioactivity	69
2.4.25 <i>Carpobrotus edulis</i>	69
2.4.25.1 Description	69
2.4.25.2 Medicinal uses	69
2.4.25.3 Phytochemistry / Bioactivity	70
2.4.26 <i>Chironia baccifera</i>	70
2.4.26.1 Description	70
2.4.26.2 Medicinal uses	70
2.4.26.3 Phytochemistry / Bioactivity	71
2.4.27 <i>Cissampelos capensis</i>	71
2.4.27.1 Description	71
2.4.27.2 Medicinal uses.....	71
2.4.27.3 Phytochemistry / Bioactivity	72
2.4.28 <i>Harpagophytum procumbens</i>	72
2.4.28.1 Description	72
2.4.28.2 Medicinal uses	72
2.4.28.3 Phytochemistry / Bioactivity	73
2.4.29 <i>Hoodia currorii</i>	73

2.4.29.1 Description	73
2.4.29.2 Medicinal uses	73
2.4.29.3 Phytochemistry / Bioactivity	74
2.4.30 <i>Nymphaea nouchali</i>	74
2.4.30.1 Description	74
2.4.30.2 Medicinal uses	74
2.4.30.3 Phytochemistry / Bioactivity	75
2.4.31 <i>Trigonella foenumgraecum</i>	75
2.4.31.1 Description	75
2.4.31.2 Medicinal uses	75
2.4.31.3 Phytochemistry / Bioactivity	75
2.4.32 <i>Vernonia oligocephala</i>	76
2.4.32.1 Description	76
2.4.32.2 Medicinal uses	76
2.4.32.3 Phytochemistry / Bioactivity	76
2.5 Conclusion	77
2.6 Acknowledgement	78
2.7 References	78

CHAPTER 3.

HYPOGLYCAEMIC ACTIVITY OF FOUR PLANT EXTRACTS TRADITIONALLY USED IN SOUTH AFRICA FOR DIABETES	86
3.1 Abstract	87
3.2 Introduction	88
3.3 Material and Methods	89
3.3.1 Plant material	89
3.3.2 Preparation of plant extracts	90
3.3.3 <i>In vitro</i> anti-diabetic and toxicity screening.....	91
3.3.4 Routine maintenance of cell cultures	91
3.3.4.1 Glucose uptake experimental procedures on C2C12 myoblast cells	91
3.3.4.2 Glucose uptake experimental procedure on Chang..... liver cells and 3T3-L1 adipose cells	92
3.3.4.3 Dose response	93
3.4 Alpha-glucosidase inhibiting activity	93
3.5 Alpha-amylase inhibiting activity	94
3.5.1 Enzyme assay	94
3.5.2 Prussian blue assay	95
3.6 Results	95
3.6.1 <i>In vitro</i>	95
3.6.2 MTT toxicity assay	98
3.6.3 Alpha-glucosidase and alpha-amalyse assay	99

3.7 Discussion	100
3.8 Acknowledgements	102
3.9 References	102

CHAPTER 4.

ISOLATION OF BIOACTIVE COMPOUNDS FROM *EUCLEA UNDULATA* var. *MYRTINA* ROOTBARK.107

4.1 Abstract	107
4.2 Introduction	107
4.3 Material and methods	107
4.3.1 Plant material	107
4.3.2 Extraction of plant material	108
4.3.3 Fractionation of the crude plant extract	108
4.4 Determination of hypoglycaemic activity	108
4.5 Results and discussion	112
4.5.1 <i>In vitro</i> test results	112
4.5.2 Alpha glycosidase assay	112
4.6 Phytochemical examination	116
4.6.1 Chemical constituents from the root bark of <i>E. undulata</i>	116
4.6.1.1 α -amyrin-3O- β -(5-hydroxy) ferulic acid (1)	116
4.6.1.2 Betulin (2).....	123
4.6.1.3 Lupeol (3).....	123
4.6.1.4 Epicatechin (4)	126
4.7 Conclusions	128
4.8 References	129

CHAPTER 5.

GENERAL DISCUSSION AND CONCLUSION.....133

CHAPTER 6.

ACKNOWLEDGEMENTS AND PUBLICATIONS138

6.1 Congresses attended	138
6.2 Publications from this thesis	139

CHAPTER 7.

REFERENCES140

CHAPTER 8.

APPENDIX158

List of Figures

Chapter 1.

- Figure 1.1: Structure of human proinsulin. Insulin is shown as the shaded peptide chains, A and B (Davis and Granner, 1996).21
- Figure 1.2: Model of the control of insulin release from the pancreatic β -cells by glucose (Nolte and Karam, 2001).....22
- Figure 1.3: Schematic diagram of the probable structure of the insulin receptor tetramer in the activated state (Nolte and Karam, 2001).....24
- Figure 1.4: Chemical structure of the first generation sulfonylurea (a)tolbutamide, (b) tolazamide (c) chlorproamide and the second generation sulfonylurea (d) glyburide (e) glipzide and (f) glimepiride (PubChem Public Chemical Database, 2009).....26
- Figure 1.5: Chemical structure of the meglitinide repaglinide (PubChem Public Chemical Database, 2009).....27
- Figure 1.6: Chemical structure of the biguanide metformin (PubChem Public Chemical Database, 2009).....28
- Figure 1.7 *Galega officinalis* Van Wyk and Wink (2004).....28
- Figure 1.8: Chemical structure of the thiazolidinediones, a) troglitazone, b) rosiglitazone and c) pioglitazone (PubChem Public Chemical Database, 2009).....29

Chapter 3

- Figure 3.1. Glucose uptake (as % of control \pm standard error of mean, N = 8 for C2C12 and 10 for Chang liver and 3T3-L1) of the various plant extracts tested for their hypoglycaemic activity.....96
- Figure 3.2. Toxicity (as % of control \pm standard error of mean, N = 6) of the various plant extracts tested for their hypoglycaemic activity.....97
- Figure 3.3. Dose response of the *E. undulata* plant extract *in vitro* on Chang liver cells (as % of control \pm standard error of mean, N = 5). Cells were exposed to 12.5 μ g/ml extract for 48 hours before glucose utilization was measured in the presence of the extract concentrations as indicated. * p <0.05; ** p <0.005 compared to untreated control (using student's two-tailed t-test).....99

Chapter 4

Figure 4.1. Silica gel column fractionation of the acetone extract of <i>E. undulata</i>	109
Figure 4.2. Dendrogram indicating the isolation of compounds from the crude acetone extract of <i>E. undulata</i> var. <i>myrtina</i>	110
Figure 4.3. Glucose uptake (as % of control \pm standard error of mean N= 8) of the different fractions of the crude plant extract of <i>E. undulata</i> (12.5 μ g/ml) tested for their hypoglycaemic activity on C2C12 myocytes.....	114
Figure 4.4. Glucose uptake (as % of control \pm standard error of mean N=8) of the compounds isolated from <i>E. undulata</i> tested for their hypoglycaemic activity on C2C12 myocytes.....	113
Figure 4.5. Inhibition of alpha-glucosidase of the various compounds isolated from the acetone extract of <i>E. undulata</i> tested for (Bars represent the means of duplicate determinations and error bars the highest and lowest values).....	115
Figure 4.6 HMBC correlations of α -amyrin-3O- β -(5-hydroxy) ferulic acid (1)	117
Figure 4.7 IR spectra of α -amyrin-3O- β -(5-hydroxy) ferulic acid (1)	117
Figure 4.8. The ^1H -NMR spectrum of α -amyrin-3O- β -(5-hydroxy) ferulic acid (1)	119
Figure 4.9. The ^{13}C NMR spectrum of α -amyrin-3O- β -(5-hydroxy) ferulic acid (1)	120
Figure 4.10. - + ESI spectrum of α -amyrin-3O- β -(5-hydroxy) ferulic acid (1)	121
Figure 4.11. The HMBC spectrum of α -amyrin-3O- β -(5-hydroxy) ferulic acid (1)	122
Figure 4.12. The HSQC spectrum of α -amyrin-3O- β -(5-hydroxy) ferulic acid (1)	122
Figure 4.13. ^1H -NMR spectrum of betulin (2)	124
Figure 4.14. ^1H -NMR spectrum of lupeol (3).....	125
Figure 4.15 ^1H -NMR spectrum of epicatechin (4).....	127

List of Tables

Chapter 3.

Table 3.1. Effect of plant extracts on glucose utilization and toxicity on Chang liver cells, 3T3-L1 preadipocytes and C2C12 myocytes using the scoring system of Van De Venter *et al.* (2008)..... .98

Table 3.2. Inhibitory effect (IC_{50}) of four plant extracts and positive control acarbose for alpha-glucosidase and alpha-amylase.....100

Chapter 4.

Table 4.1 Inhibitory affect (IC_{50}) of the four compounds and positive control acarbose for alpha-glucosidase115

Table 4.2 NMR data of α -amyrin-3O- β -(5-hydroxy) ferulic acid (1).....118